Alder BioPharmaceuticals Company Profile (NASDAQ:ALDR)

About Alder BioPharmaceuticals

Alder BioPharmaceuticals logoAlder Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company discovers, develops and focuses to commercialize therapeutic antibodies with the potential to transform current treatment paradigms. The Company has developed an antibody platform designed to select antibodies that have the potential to maximize efficacy, as well as speed of onset and durability of therapeutic response. The Company's pipeline includes ALD403, Clazakizumab and ALD1613. ALD403 is the Company's monoclonal antibody targeted to calcitonin gene-related peptide (CGRP) for migraine prevention. Clazakizumab is a monoclonal antibody that inhibits the pro-inflammatory cytokine interleukin-6 (IL-6), and is in development for both rheumatoid arthritis (RA) and psoriatic arthritis (PsA). ALD1613 is a monoclonal antibody that inhibits Adrenocorticotropic Hormone (ACTH), and is being developed for the treatment of Cushing's disease. It is also developing ALD403 program for migraine prevention.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: ALDR
  • CUSIP:
Key Metrics:
  • Previous Close: $34.31
  • 50 Day Moving Average: $32.14
  • 200 Day Moving Average: $27.89
  • 52-Week Range: $15.82 - $39.43
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.69
  • P/E Growth: -0.49
  • Market Cap: $1.67B
  • Outstanding Shares: 50,184,000
  • Beta: 2.68
  • Return on Equity: -31.06%
  • Return on Assets: -29.98%
  • Current Ratio: 28.72%
  • Quick Ratio: 28.66%
Additional Links:
Companies Related to Alder BioPharmaceuticals:

Analyst Ratings

Consensus Ratings for Alder BioPharmaceuticals (NASDAQ:ALDR) (?)
Ratings Breakdown: 6 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $46.75 (40.18% upside)

Analysts' Ratings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
DateFirmActionRatingPrice TargetDetails
9/28/2016Jefferies GroupReiterated RatingBuy$62.00View Rating Details
9/13/2016JPMorgan Chase & Co.Initiated CoverageOverweight$40.00View Rating Details
7/27/2016Brean CapitalReiterated RatingPositive$45.00View Rating Details
4/21/2016Wells Fargo & Co.Initiated CoverageOutperformView Rating Details
3/29/2016Leerink SwannReiterated RatingOutperformView Rating Details
3/29/2016Credit Suisse Group AGReiterated RatingOutperform$40.00View Rating Details
(Data available from 9/29/2014 forward)


Earnings History for Alder BioPharmaceuticals (NASDAQ:ALDR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/26/2016Q2($0.75)($0.79)$1.14 million$0.11 millionViewListenView Earnings Details
4/28/2016Q1($0.72)($0.76)$0.14 millionViewN/AView Earnings Details
2/23/2016Q4($0.65)($0.60)ViewListenView Earnings Details
11/5/2015Q315($0.51)($0.62)$0.23 millionViewN/AView Earnings Details
8/5/2015Q215($0.40)($0.46)$0.23 millionViewN/AView Earnings Details
5/7/2015Q115($0.39)($0.40)ViewListenView Earnings Details
3/4/2015Q414$0.21($0.22)$5.70 million$6.40 millionViewN/AView Earnings Details
11/3/2014Q314$0.05$0.88$14.84 million$38.75 millionViewN/AView Earnings Details
8/5/2014Q2($0.25)($0.40)$5.00 million$4.70 millionViewN/AView Earnings Details
6/18/2014Q1($5.38)$4.60 million$4.80 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Alder BioPharmaceuticals (NASDAQ:ALDR)
Current Year EPS Consensus Estimate: $-3.33 EPS
Next Year EPS Consensus Estimate: $-3.44 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20163($0.74)($0.66)($0.71)
Q2 20162($0.80)($0.78)($0.79)
Q3 20162($0.89)($0.87)($0.88)
Q4 20162($1.01)($0.93)($0.97)
(Data provided by Zacks Investment Research)


Dividend History for Alder BioPharmaceuticals (NASDAQ:ALDR)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading History for Alder BioPharmaceuticals (NASDAQ:ALDR)
Insider Ownership Percentage: 11.50%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/1/2016Jeffrey T L SmithVPSell3,000$32.49$97,470.00View SEC Filing  
9/1/2016Randall C SchatzmanInsiderSell10,000$32.48$324,800.00View SEC Filing  
8/15/2016Jeffrey T L SmithVPSell3,000$31.17$93,510.00View SEC Filing  
8/1/2016John A LathamInsiderSell10,000$31.19$311,900.00View SEC Filing  
7/27/2016John A LathamInsiderSell10,000$30.14$301,400.00View SEC Filing  
7/25/2016Randall C SchatzmanInsiderSell10,000$28.08$280,800.00View SEC Filing  
6/13/2016Mark James LittonInsiderSell6,000$28.94$173,640.00View SEC Filing  
6/3/2016Jeffrey T L SmithVPSell16,090$30.20$485,918.00View SEC Filing  
6/1/2016John A LathamInsiderSell10,000$30.02$300,200.00View SEC Filing  
5/31/2016Mark James LittonInsiderSell25,000$30.05$751,250.00View SEC Filing  
5/27/2016John A LathamInsiderSell6,401$30.05$192,350.05View SEC Filing  
5/24/2016Randall C SchatzmanCEOSell10,000$28.02$280,200.00View SEC Filing  
4/18/2016Randall C SchatzmanCEOSell30,000$28.07$842,100.00View SEC Filing  
1/4/2016Mark James LittoninsiderSell25,000$31.40$785,000.00View SEC Filing  
1/4/2016Randall C. SchatzmanCEOSell10,000$31.47$314,700.00View SEC Filing  
12/1/2015Jeffrey T. L. SmithVPSell4,272$37.24$159,089.28View SEC Filing  
12/1/2015John A. LathaminsiderSell4,550$37.24$169,442.00View SEC Filing  
12/1/2015Randall C. SchatzmanCEOSell10,000$37.24$372,400.00View SEC Filing  
11/30/2015Stephen M DowDirectorSell88$37.11$3,265.68View SEC Filing  
11/2/2015Jeffrey T. L. SmithVPSell3,900$33.67$131,313.00View SEC Filing  
11/2/2015John A. LathaminsiderSell4,545$33.69$153,121.05View SEC Filing  
11/2/2015Randall C. SchatzmanCEOSell10,000$33.71$337,100.00View SEC Filing  
10/1/2015Jeffrey T. L. SmithVPSell3,900$32.25$125,775.00View SEC Filing  
10/1/2015John A. LathaminsiderSell4,545$32.26$146,621.70View SEC Filing  
9/1/2015Jeffrey T. L. SmithVPSell3,900$38.50$150,150.00View SEC Filing  
9/1/2015John A. LathaminsiderSell4,545$38.52$175,073.40View SEC Filing  
8/31/2015Stephen M DowDirectorSell16,218$38.75$628,447.50View SEC Filing  
6/12/2015Larry BenedictVPSell25,454$47.46$1,208,046.84View SEC Filing  
6/4/2015John A LathamInsiderSell25,000$44.18$1,104,500.00View SEC Filing  
6/1/2015Jeffrey T L SmithVPSell3,900$41.53$161,967.00View SEC Filing  
6/1/2015John A LathamInsiderSell4,545$41.53$188,753.85View SEC Filing  
5/22/2015Jeffrey T L SmithVPSell61,818$38.86$2,402,247.48View SEC Filing  
5/21/2015Stephen M DowDirectorSell20,000$65.69$1,313,800.00View SEC Filing  
5/20/2015Stephen M DowDirectorSell8,462$40.39$341,780.18View SEC Filing  
5/18/2015Clay B SiegallDirectorSell38,181$37.62$1,436,369.22View SEC Filing  
4/1/2015Jeffrey T L SmithVPSell3,900$27.43$106,977.00View SEC Filing  
4/1/2015John A LathamInsiderSell19,045$29.54$562,589.30View SEC Filing  
3/30/2015John A LathamInsiderSell14,500$30.20$437,900.00View SEC Filing  
1/27/2015Jeffrey T L SmithVPSell3,900$28.01$109,239.00View SEC Filing  
1/27/2015John A LathamInsiderSell15,045$28.33$426,224.85View SEC Filing  
1/27/2015Randall C SchatzmanCEOSell100,000$28.42$2,842,000.00View SEC Filing  
1/26/2015Jeffrey T L SmithVPSell2,700$27.89$75,303.00View SEC Filing  
1/26/2015Mark James LittonInsiderSell5,200$28.03$145,756.00View SEC Filing  
1/26/2015Randall C SchatzmanCEOSell36,422$27.93$1,017,266.46View SEC Filing  
11/24/2014Jeffrey T L SmithVPSell29,090$16.08$467,767.20View SEC Filing  
5/13/2014A/S NovoInsiderBuy550,000$10.00$5,500,000.00View SEC Filing  
5/13/2014Alan Bruce MontgomeryDirectorBuy3,000$10.00$30,000.00View SEC Filing  
5/13/2014West 8 Limited Partne VenturesMajor ShareholderBuy250,000$10.00$2,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for Alder BioPharmaceuticals (NASDAQ:ALDR)
News IconTraders Focused Stock: Tahoe Resources, Inc. (NYSE:TAHO) , Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) - Wall Street Times (press release) (NASDAQ:ALDR) - September 28 at 3:23 PM logoShares Of Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Expected To Hit $62 - Investor Newswire (NASDAQ:ALDR) - September 24 at 3:24 PM logoAllergan's Boldness may not be Limited to Tobira Deal - (NASDAQ:ALDR) - September 22 at 3:24 PM logoAlder BioPharmaceuticals Appoints Nancy L. Boman, M.D., Ph.D., Senior Vice President of Regulatory Affairs and Pharmacovigilance (NASDAQ:ALDR) - September 21 at 9:55 AM logoDELTA DRONE’s acquisition of ROCKETMINE South Africa (NASDAQ:ALDR) - September 19 at 4:20 PM
News IconAlder Biopharmaceuticals Inc (ALDR) Insider John A. Latham Sells ... - DailyQuint (NASDAQ:ALDR) - September 18 at 8:14 AM logoAlder BioPharma (ALDR) Announces Presentation of Positive ... - (NASDAQ:ALDR) - September 15 at 3:24 PM logoAlder BioPharma (ALDR) Announces Presentation of Positive ALD403 Phase 2b Data in Migraine Prevention (NASDAQ:ALDR) - September 15 at 12:18 PM logo8:00 am Alder BioPharmaceuticals presents 'positive' data from Phase 2b and Phase 1 clinical trials of ALD403 for the prevention of migraine at the 5th European Headache and Migraine Trust International Congress (NASDAQ:ALDR) - September 15 at 12:18 PM logoAlder Presents Positive ALD403 Clinical Data at European Headache and Migraine Trust International Congress (NASDAQ:ALDR) - September 15 at 12:18 PM
News IconAlder BioPharmaceuticals Inc. (NASDAQ: ALDR) Stock Coverage Initiated at JPMorgan Chase & Co. - The Woodbridge Citizen (NASDAQ:ALDR) - September 14 at 3:24 PM logoAlder Biopharmaceuticals, Inc. – Value Analysis (NASDAQ:ALDR) : September 14, 2016 (NASDAQ:ALDR) - September 14 at 3:24 PM logoCoverage initiated on Alder BioPharmaceuticals by JP Morgan (NASDAQ:ALDR) - September 13 at 3:24 PM logoAlder Biopharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : ALDR-US : September 13, 2016 (NASDAQ:ALDR) - September 13 at 3:24 PM
News IconSteering Attention Towards Earnings; Analysts Weigh in on Alder ... - Frisco Fastball (NASDAQ:ALDR) - September 9 at 3:29 PM
News IconPartner Fund Management buys $110282601 stake in Alder Biopharmaceuticals Inc (ALDR) - National Daily Press (NASDAQ:ALDR) - September 9 at 3:29 PM
News IconStock Slipping Down Over the Past Five Trading Sessions: Alder ... - National Daily Press (NASDAQ:ALDR) - September 9 at 8:12 AM logoSubscription of one block of 1 million euros under the February 2015 contract for convertible notes with attached warrants (NASDAQ:ALDR) - September 8 at 3:23 PM
News IconAlder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting ... - EconoTimes (NASDAQ:ALDR) - September 8 at 11:26 AM logoAlder Announces Presentations at the European Headache and Migraine Trust International Congress Supporting Development of ALD403 for Migraine Prevention (NASDAQ:ALDR) - September 8 at 11:26 AM logoAlder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief ... - GlobeNewswire (press release) (NASDAQ:ALDR) - September 6 at 3:24 PM logoAlder BioPharmaceuticals Appoints Elisabeth A. Sandoval as Chief Commercial Officer (NASDAQ:ALDR) - September 6 at 8:12 AM logoImplementation of a liquidity agreement with with Louis Capital Markets (NASDAQ:ALDR) - September 5 at 8:11 AM logoAlder BioPharmaceuticals to Present at Two Upcoming September Healthcare Conferences - GlobeNewswire (press release) (NASDAQ:ALDR) - August 31 at 8:11 AM logoUnder Armour, Starbucks, Alder Biopharmaceuticals, YY, and Google and more offer option-trading opportunities that offer returns of more than 20% (NASDAQ:ALDR) - August 31 at 8:11 AM logoAlder BioPharmaceuticals to Present at Two Upcoming September Healthcare Conferences (NASDAQ:ALDR) - August 31 at 8:11 AM logoAlder Biopharmaceuticals (ALDR) Jumps: Stock Rises 9.6% - Yahoo Finance (NASDAQ:ALDR) - August 25 at 3:28 PM
News IconJefferies Group Reiterates Buy at Alder BioPharmaceuticals Inc. (NASDAQ: ALDR) - BNB Daily (blog) (NASDAQ:ALDR) - August 24 at 11:43 AM
News IconStock's Buzz: Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), Valeant Pharmaceuticals International, Inc. (NYSE:VRX) - Newburg Press (NASDAQ:ALDR) - August 23 at 3:27 PM logoMomentum Stocks: VeriSign, Inc. (VRSN), Alder Biopharmaceuticals Inc. (ALDR), CubeSmart (CUBE) - iStreetWire (NASDAQ:ALDR) - August 23 at 8:26 AM
News IconStock Moving Up in Session: Alder Biopharmaceuticals Inc. (NASDAQ:ALDR) - Post News (NASDAQ:ALDR) - August 22 at 3:29 PM logoWill Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR) Hit $62 Price Target? - Investor Newswire (NASDAQ:ALDR) - August 20 at 3:26 PM logoAlder Biopharmaceuticals : How These Biotech Stocks are Faring? -- bluebird bio, Sage Therapeutics, Ultragenyx Pharma, and Alder Biopharma (NASDAQ:ALDR) - August 10 at 10:35 AM logoDelta Drone is in exclusive negotiations for the acquisition of substantially all of the assets of NM, LLC based in the US (NASDAQ:ALDR) - August 8 at 3:28 PM logoEvolution of the share capital and shareholdings of Delta Drone (NASDAQ:ALDR) - August 3 at 9:03 PM logoJefferies Maintains Alder Biopharmaceuticals Inc to Buy with Price ... - Trade Calls (NASDAQ:ALDR) - August 3 at 3:30 PM logoDelta Drone SA :ALDR-FR: Earnings Analysis: For the six months ended December 31, 2015 : August 3, 2016 (NASDAQ:ALDR) - August 3 at 12:00 PM
News IconFeatured Biotechnology Stocks: Halozyme Therapeutics, Inc. (NASDAQ:HALO), Alder Biopharmaceuticals Inc ... - Post Registrar (NASDAQ:ALDR) - August 2 at 3:27 PM logoRecent Trading Alert: Zoetis Inc. (NYSE:ZTS) , Alder ... - Street Updates - Street Updates (NASDAQ:ALDR) - August 2 at 8:11 AM logoALDER BIOPHARMACEUTICALS INC Financials (NASDAQ:ALDR) - July 30 at 1:04 PM logoAlder BioPharmaceuticals Inc. (ALDR) Jumps 6.13% on July 25 - (NASDAQ:ALDR) - July 27 at 12:02 PM logoHere’s What’s Important About Alder Biopharmaceuticals Inc (ALDR)’s Latest Release (NASDAQ:ALDR) - July 27 at 9:27 AM logoEdited Transcript of ALDR earnings conference call or presentation 26-Jul-16 9:00pm GMT (NASDAQ:ALDR) - July 27 at 3:56 AM logoMigraine treatment company Alder reports loss, spends more on research (NASDAQ:ALDR) - July 26 at 9:29 PM
News IconAlder BioPharmaceuticals Reports Second Quarter 2016 Financial and Operating Results (NASDAQ:ALDR) - July 26 at 9:29 PM logoAlder BioPharmaceuticals : posts 2Q loss (NASDAQ:ALDR) - July 26 at 9:29 PM logoAlder BioPharmaceuticals posts 2Q loss (NASDAQ:ALDR) - July 26 at 5:53 PM logoHere's What's Important About Alder Biopharmaceuticals Inc ... - Market Exclusive (NASDAQ:ALDR) - July 26 at 3:25 PM logoAlder BioPharma (ALDR) Announces Positive Top-Line Data from ALD403 Phase 2b (NASDAQ:ALDR) - July 26 at 12:57 PM logoHere’s What’s Important About Alder Biopharmaceuticals Inc (NASDAQ:ALDR)’s Latest Release (NASDAQ:ALDR) - July 26 at 12:57 PM


Alder BioPharmaceuticals (NASDAQ:ALDR) Chart for Thursday, September, 29, 2016

Last Updated on 9/29/2016 by Staff